Clinical Trial Update: Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase II trial update investigating sequential AG and FOLFIRINOX as neoadjuvant therapy in patients with resectable pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• AG
• FOLFIRINOX

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Resectable Pancreatic Cancer | Phase 2 | Status: UNKNOWN